Comparison · NCT01774604-4cddad8b
Indomethacin vs Placebo: Number of Patients Who Developed Gastrointestinal Bleeding
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Indomethacin vs Placebo: Number of Patients Who Developed Gastrointestinal Bleeding. Trial comparisons, record NCT01774604-4cddad8b. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01774604-4cddad8b
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0179 | 0.007 | 0.0452 | wilson | |
| Risk in group 2 | 0.0265 | 0.0122 | 0.0567 | wilson | |
| Risk difference, group 1 minus group 2 | -0.00861 | -0.0407 | 0.0222 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.676 | 0.193 | 2.36 | log | |
| Odds ratio, group 1 over group 2 | 0.67 | 0.186 | 2.41 | log | |
| Number needed to treat, for one fewer participant with the outcome on Indomethacin than on Placebo | 116 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Indomethacin | Indomethacin 100 mg PR x 1 in peri-procedural period~Indomethacin: 100 mg Indomethacin PR x 1 | 4 | 223 | OG000 |
| Group 2 | Placebo | Placebo suppositories (#2)~Placebo | 6 | 226 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Number of Patients Who Developed Gastrointestinal Bleeding
- Description
- Number of patients who developed any type of gastrointestinal bleeding from time of ERCP to 30 days post procedure
- Time frame
- From randomization to 30 days after ERCP
- Population
Source ClinicalTrials.gov
Trial
- Title
- Rectal Indomethacin to Prevent Post-Endoscopic Retrograde Cholangiopancreatography (ERCP) Pancreatitis
- NCT number
- NCT01774604
- Phases
- PHASE3
- Conditions
- Post-ERCP Acute Pancreatitis
- Interventions
- Indomethacin, Placebo
- Lead sponsor
- Dartmouth-Hitchcock Medical Center
- Results first posted
- 2016-09-20
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT01774604?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT01774604-4cddad8b